Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 178-185

  Schiffer, Sonja ^a,b   Letzian, Soriba ^b   Jost, Edgar ^c   Mladenov, Radoslav ^a   Hristodorov, Dmitrij ^a   Huhn, Michael ^a   Fischer, Rainer ^b   Barth, Stefan ^a,b   Thepen, Theo ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Immunotherapy; Immunotoxin; Serine protease; Serpin B9

Indexed keywords

ANTILEUKEMIC AGENT; CD64 ANTIGEN; GRANZYME; GRANZYME M; GRANZYME M SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY H22 FUSION PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG; FC RECEPTOR; IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TARGETING; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HL 60 CELL LINE; IMMUNOLOGY; K562 CELL LINE; LEUKEMIA; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GRANZYMES; HEK293 CELLS; HL-60 CELLS; HUMANS; IMMUNOTOXINS; K562 CELLS; LEUKEMIA; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR CELLS, CULTURED;

EID: 84887208545     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.005     Document Type: Article

References (48)

1. Madhumathi J., Verma R.S. Therapeutic targets and recent advances in protein immunotoxins. Curr. Opin. Microbiol. 2012, 15:300-309.
2. Khazaeli M.B., Conry R.M., Lobuglio A.F. Human immune-response to monoclonal-antibodies. J. Immunother. 1994, 15:42-52.
3. Mathew M., Verma R.S. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci. 2009, 100:1359-1365.
4. Grossman W.J., Revell P.A., Lu Z.H., Johnson H., Bredemeyer A.J., Ley T.J. The orphan granzymes of humans and mice. Curr. Opin. Immunol. 2003, 15:544-552.
5. Trapani J.A. Granzymes: a family of lymphocyte granule serine proteases. Genome Biol. 2001, 2. (REVIEWS3014).
6. Kurschus F.C., Jenne D.E. Delivery and therapeutic potential of human granzyme B. Immunol. Rev. 2010, 235:159-171.
7. Hehmann-Titt G., Schiffer S., Berges N., Melmer G., Barth S. Improving the therapeutic potential of human granzyme B for targeted cancer therapy. Antibodies 2013, 2:19-49.
8. Bladergroen B.A., Meijer C.J., ten Berge R.L., Hack C.E., Muris J.J., Dukers D.F., Chott A., Kazama Y., Oudejans J.J., van Berkum O., Kummer J.A. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?. Blood 2002, 99:232-237.
9. ten Berge R.L., Meijer C.J., Dukers D.F., Kummer J.A., Bladergroen B.A., Vos W., Hack C.E., Ossenkoppele G.J., Oudejans J.J. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002, 99:4540-4546.
10. Losasso V., Schiffer S., Barth S., Carloni P. Design of human granzyme B variants resistant to serpin B9. Proteins 2012.
11. Smyth M.J., O'Connor M.D., Trapani J.A., Kershaw M.H., Brinkworth R.I. A novel substrate-binding pocket interaction restricts the specificity of the human NK cell-specific serine protease, Met-ase-1. J. Immunol. 1996, 156:4174-4181.
12. Susanto O., Trapani J.A., Brasacchio D. Controversies in granzyme biology. Tissue Antigens 2012, 80:477-487.
13. Pegram H.J., Haynes N.M., Smyth M.J., Kershaw M.H., Darcy P.K. Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunol. Immun.: CII 2010, 59:1235-1246.
14. Bovenschen N., de Koning P.J., Quadir R., Broekhuizen R., Damen J.M., Froelich C.J., Slijper M., Kummer J.A. NK cell protease granzyme M targets alpha-tubulin and disorganizes the microtubule network. J. Immunol. 2008, 180:8184-8191.
15. Cullen S.P., Afonina I.S., Donadini R., Luthi A.U., Medema J.P., Bird P.I., Martin S.J. Nucleophosmin is cleaved and inactivated by the cytotoxic granule protease granzyme M during natural killer cell-mediated killing. J. Biol. Chem. 2009, 284:5137-5147.
16. Hu D., Liu S., Shi L., Li C., Wu L., Fan Z. Cleavage of survivin by granzyme M triggers degradation of the survivin-X-linked inhibitor of apoptosis protein (XIAP) complex to free caspase activity leading to cytolysis of target tumor cells. J. Biol. Chem. 2010, 285:18326-18335.
17. Hua G., Zhang Q., Fan Z. Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J. Biol. Chem. 2007, 282:20553-20560.
18. Kelly J.M., Waterhouse N.J., Cretney E., Browne K.A., Ellis S., Trapani J.A., Smyth M.J. Granzyme M mediates a novel form of perforin-dependent cell death. J. Biol. Chem. 2004, 279:22236-22242.
19. Lu H., Hou Q., Zhao T., Zhang H., Zhang Q., Wu L., Fan Z. Granzyme M directly cleaves inhibitor of caspase-activated DNase (CAD) to unleash CAD leading to DNA fragmentation. J. Immunol. 2006, 177:1171-1178.
20. Wang S., Xia P., Shi L., Fan Z. FADD cleavage by NK cell granzyme M enhances its self-association to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascade. Cell Death Differ. 2012, 19:605-615.
21. de Poot S.A.H., Westgeest M., Hostetter D.R., Van Damme P., Plasman K., Demeyer K., Broekhuizen R., Gevaert K., Craik C.S., Bovenschen N. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem. J. 2011, 437:431-442.
22. Mahrus S., Kisiel W., Craik C.S. Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J. Biol. Chem. 2004, 279:54275-54282.
23. Anthony D.A., Andrews D.M., Chow M., Watt S.V., House C., Akira S., Bird P.I., Trapani J.A., Smyth M.J. A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J. Immunol. 2010, 185:1794-1803.
24. Tur M.K., Huhn M., Jost E., Thepen T., Brummendorf T.H., Barth S. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model. Int. J. Cancer 2011, 129:1277-1282.
25. Tur M.K., Huhn M., Thepen T., Stocker M., Krohn R., Vogel S., Jost E., Osieka R., van de Winkel J.G., Fischer R., Finnern R., Barth S. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 2003, 63:8414-8419.
26. Stahnke B., Thepen T., Stocker M., Rosinke R., Jost E., Fischer R., Tur M.K., Barth S. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol. Cancer Ther. 2008, 7:2924-2932.
27. Ball E.D., McDermott J., Griffin J.D., Davey F.R., Davis R., Bloomfield C.D. Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood 1989, 73:1951-1956.
28. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
29. Thepen T., van Vuuren A.J.H., Kiekens R.C.M., Damen C.A., Vooijs W.C., van de Winkel J.G.J. Resolution of cutaneous inflammation after local elimination of macrophages. Nat. Biotechnol. 2000, 18:48-51.
30. Christiansen J., Rajasekaran A.K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 2004, 3:1493-1501.
31. Schiffer S., Hansen H., Hehmann-Titt G., Huhn M., Fischer R., Barth S., Thepen T. Efficacy of an adapted Granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. Blood Cancer J. 2013, 3:e106.
32. Pasternak A., Ringe D., Hedstrom L. Comparison of anionic and cationic trypsinogens: the anionic activation domain is more flexible in solution and differs in its mode of BPTI binding in the crystal structure. Protein Sci.: Publ. Protein Soc. 1999, 8:253-258.
33. Horn-Lohrens O., Tiemann M., Lange H., Kobarg J., Hafner M., Hansen H., Sterry W., Parwaresch R.M., Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int. J. Cancer 1995, 60:539-544.
34. Kanatani I., Lin X., Yuan X., Manorek G., Shang X., Cheung L.H., Rosenblum M.G., Howell S.B. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemother. Pharmacol. 2011, 68:979-990.
35. Bots M., Bostelen V.A.N., Rademaker M.T., Offringa R., Medema J.P. Serpins prevent granzyme-induced death in a species-specific manner. Immunol. Cell Biol. 2006, 84:79-86.
36. Tewari M., Telford W.G., Miller R.A., Dixit V.M. CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis. J. Biol. Chem. 1995, 270:22705-22708.
37. Quan L.T., Caputo A., Bleackley R.C., Pickup D.J., Salvesen G.S. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J. Biol. Chem. 1995, 270:10377-10379.
38. Law R.H., Zhang Q., McGowan S., Buckle A.M., Silverman G.A., Wong W., Rosado C.J., Langendorf C.G., Pike R.N., Bird P.I., Whisstock J.C. An overview of the serpin superfamily. Genome Biol. 2006, 7:216.
39. Sun J., Bird C.H., Sutton V., McDonald L., Coughlin P.B., De Jong T.A., Trapani J.A., Bird P.I. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 1996, 271:27802-27809.
40. Sutton V.R., Wowk M.E., Cancilla M., Trapani J.A. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003, 18:319-329.
41. de Koning P.J., Kummer J.A., de Poot S.A., Quadir R., Broekhuizen R., McGettrick A.F., Higgins W.J., Devreese B., Worrall D.M., Bovenschen N. Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS ONE 2011, 6:e22645.
42. Jiang X., Ellison S.J., Alarid E.T., Shapiro D.J. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 2007, 26:4106-4114.
43. Rousalova I., Krepela E., Prochazka J., Cermak J., Benkova K. Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues. Int. J. Oncol. 2010, 36:275-283.
44. Soriano C., Mukaro V., Hodge G., Ahern J., Holmes M., Jersmann H., Moffat D., Meredith D., Jurisevic C., Reynolds P.N., Hodge S. Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion?. Lung Cancer 2012, 77:38-45.
45. van Houdt I.S., Oudejans J.J., van den Eertwegh A.J., Baars A., Vos W., Bladergroen B.A., Rimoldi D., Muris J.J., Hooijberg E., Gundy C.M., Meijer C.J., Kummer J.A. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin. Cancer Res. 2005, 11:6400-6407.
46. de Koning P.J., Kummer J.A., Bovenschen N. Biology of granzyme M: a serine protease with unique features. Crit. Rev. Immunol. 2009, 29:307-315.
47. Hristodorov D., Mladenov R., Huhn M., Barth S., Thepen T. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins 2012, 4:676-694.
48. Schiffer S., Hristodorov D., Mladenov R., Aslanian E., Huhn M., Fischer R., Barth S., Thepen T. Species-dependent functionality of the human cytolytic fusion proteins granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages. Antibodies 2013, 2:9-18.